EW
Edwards Lifesciences Corporation
Price performance
Sep 18, 2026About
Company activity
27 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 08/28 | EW | 8-K | Donald E. Bobo, Jr. to Retire from Edwards Lifesciences | — | — | — |
| 07/23 | EW | 8-K | Edwards Lifesciences Reports Q2 2026 Financial Results and Updates Guidance | — | — | — |
| 05/08 | EW | 8-K | Edwards Lifesciences Approves Amended Long-Term Stock Incentive Compensation Program | — | — | — |
| 05/04 | EW | 8-K | Edwards Lifesciences Appoints Theodora Mistras as New CFO | — | — | — |
| 04/23 | EW | 8-K | Edwards Lifesciences Reports Strong Q1 2026 Financial Results and Raises Guidance | — | — | — |
| 02/10 | EW | 8-K | Edwards Lifesciences Reports Strong Q4 and Full-Year 2025 Results | — | — | — |
| 01/09 | EW | 8-K | Edwards Lifesciences Acquisition Blocked by Injunction | — | — | — |
| 10/30/25 | EW | 8-K | Edwards Lifesciences Reports Strong Third Quarter Financial Results | — | — | — |
| 10/30/25 | EW | 8-K | Edwards Lifesciences Announces CFO Transition Plan | — | — | — |
| 08/19/25 | EW | 8-K | Edwards Lifesciences Announces Accelerated Share Repurchase Agreement | — | — | — |
| 08/06/25 | EW | 8-K | Edwards Lifesciences Announces FTC Move to Block JenaValve Acquisition | — | — | — |
| 07/25/25 | EW | 8-K | Edwards Lifesciences Announces Corporate Vice President Resignation | — | — | — |
| 07/24/25 | EW | 8-K | Edwards Lifesciences Reports Strong Q2 Results with 11.9% Sales Growth and Earnings Beat | — | — | — |
| 05/08/25 | EW | 8-K | Edwards Lifesciences Announces Stockholder Approvals and Officer Appointments | — | — | — |
| 04/23/25 | EW | 8-K | Edwards Lifesciences Reports Strong Q1 2025 Results | — | — | — |
| 02/11/25 | EW | 8-K | Edwards Lifesciences Reports 9% Sales Growth in Q4 2024 with Earnings Beat | — | — | — |
| 10/24/24 | EW | 8-K | Edwards Lifesciences Reports Q3 2024 Financial Results | — | — | — |
| 09/03/24 | EW | 8-K | Edwards Lifesciences Announces Sale of Critical Care Product Group and Share Repurchase Program | — | — | — |
| 07/24/24 | EW | 8-K | Edwards Lifesciences Announces Q2 2024 Results and Acquisitions | — | — | — |
| 07/15/24 | EW | 8-K | Edwards Lifesciences Announces Acquisition of Innovalve | — | — | — |
| 07/10/24 | EW | 8-K | Edwards Lifesciences Appoints Dr. David T. Feinberg to Board | — | — | — |
| 06/17/24 | EW | 8-K | Edwards Lifesciences Announces Retirement of Principal Accounting Officer | — | — | — |
| 06/03/24 | EW | 8-K | Edwards Lifesciences to Sell Critical Care to BD for $4.2 Billion | — | — | — |
| 05/08/24 | EW | 8-K | Edwards Lifesciences Corporation Announces Voting Results from Annual Meeting | — | — | — |
| 04/25/24 | EW | 8-K | Edwards Lifesciences Reports Q1 2024 Financial Results and Raises Guidance | — | — | — |
| 03/26/24 | EW | 8-K | Edwards Lifesciences Announces Leadership Changes | — | — | — |
| 02/06/24 | EW | 8-K | Edwards Lifesciences Reports Fourth Quarter 2023 Financial Results | — | — | — |
EW filing record
Edwards Lifesciences Corporation (EW): 27 8-K filings summarized, the most recent on Aug 28, 2026.
What the 8-K filings said
- Aug 28, 2026 · high impact
Edwards Lifesciences Corporation announced that Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, has decided to retire by mid-year 2027. The company will initiate a selection process for his successor, with an expected transition during 2027. Mr. Bobo will also serve as a consultant…
Donald E. Bobo, Jr. to Retire from Edwards Lifesciences - Jul 23, 2026 · high impact
Edwards Lifesciences Corporation reported a 13.6% increase in Q2 2026 sales to $1.74 billion, with constant currency sales growth of 12.5%. The company's Q2 earnings per share (EPS) was $0.42, and adjusted EPS was $0.78. Edwards increased its full-year 2026 sales growth guidance to 10% to 11%, TAVR sales growth…
Edwards Lifesciences Reports Q2 2026 Financial Results and Updates Guidance - May 8, 2026 · medium impact
Edwards Lifesciences Corporation's stockholders approved the amendment and restatement of the Company's Long-Term Stock Incentive Compensation Program at the 2026 Annual Meeting of Stockholders. The amendment increased the total number of shares of Edwards common stock available for issuance under the Long-Term Stock…
Edwards Lifesciences Approves Amended Long-Term Stock Incentive Compensation Program - May 4, 2026 · high impact
Edwards Lifesciences Corporation announced on May 4, 2026, the appointment of Theodora ('Doretta') Mistras as its new Corporate Vice President and Chief Financial Officer, effective May 29, 2026. Mistras, previously CFO of Viatris, Inc., brings extensive experience in global finance leadership. She will succeed Scott…
Edwards Lifesciences Appoints Theodora Mistras as New CFO - Apr 23, 2026 · high impact
Edwards Lifesciences reported a 16.7% increase in sales for Q1 2026, reaching $1.65 billion. TAVR sales grew by 14.4% to $1.20 billion, and TMTT sales increased by 51.9% to $173 million. The company raised its full-year 2026 sales growth guidance to 9% to 11% and adjusted its full-year 2026 adjusted EPS guidance to a…
Edwards Lifesciences Reports Strong Q1 2026 Financial Results and Raises Guidance
SEC filings in the last five years
- 38 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K